Antibody fragment imaging specialist ImaginAb signed a master service agreement with Singapore Radiopharmaceuticals, a Fortis HealthCare subsidiary that provides GMP radiopharmaceutical production services. ImaginAb is developing antibody fragment-based PET imaging agents for use in the clinical management of autoimmune diseases and cancer, and is establishing R&D and preclinical imaging capabilities in Singapore.
"The deal with Singapore Radiopharmaceuticals represents a key component in this expansion program," comments Christian Behrenbruch, Ph.D., CEO. “Singapore Radiopharmaceuticals has an excellent track record in custom radiochemistry and cGMP product manufacturing, and we are pleased to transition our ad hoc collaboration to more robust alliance.”
ImaginAb’s in-house pipeline includes early clinical-stage products for imaging and staging prostate, pancreatic, and breast cancers. The firm separately has over a dozen partnered programs in progress to develop companion diagnostic imaging agents for use alongside therapeutic antibody drugs in clinical trials. Partnered projects are exploiting the ability to reengineer a therapeutic monoclonal antibody or antibody-drug conjugate into an imaging agent that retains the same biospecificity of the parent product, but exhibits kinetics suitable for clinical imaging using low-cost isotopes. ImaginAb claims this ability to develop imaging antibodies that retain the same binding characteristics as the therapeutic antibody could represent a transformative technology for patient selection, monitoring treatment responses and looking for new therapeutic indications for antibodies.